Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
ID: 348713Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348713

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-208.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of mechanisms associated with NPS in individuals with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). This initiative encourages innovative research proposals that explore both neurobiological and behavioral pathways, potentially leading to novel therapeutic approaches for treating and preventing NPS. The R21 exploratory/developmental grant mechanism is particularly suited for high-risk projects without preliminary data, while R01 grants are recommended for longer-term studies with existing findings. Interested applicants must adhere to NIH guidelines and submit their proposals by September 7, 2026, with a maximum funding amount of $275,000. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-208.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-208-Full-Announcement.html
    PAR-23-208.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia." This initiative aims to support studies that improve understanding of mechanisms associated with NPS in individuals with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). It encourages innovative applications exploring both neurobiological and behavioral pathways, potentially leading to novel therapeutic approaches. The R21 exploratory/developmental grant mechanism is highlighted, suitable for high-risk projects without preliminary data, while R01 grants are better for longer-term projects with previous findings. Key dates include an application acceptance period starting September 16, 2023, with an expiration date of September 8, 2026. Eligible organizations encompass diverse educational institutions, non-profit entities, and governmental agencies. Applications should adhere strictly to NIH guidelines for formatting and submission, involve multi-level analysis of NPS, and align with the NIH's objectives in developing interventions targeting such neuropsychiatric challenges. Investigators are also expected to share findings through NIH-designated data repositories, enhancing transparency and collaborative research efforts in Alzheimer's research. Overall, this funding opportunity seeks to unlock mechanistic insights critically needed for advancing treatment strategies for neuropsychiatric symptoms in dementia.
    Similar Opportunities
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at advancing research on neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative encourages applications for studies that enhance understanding of the mechanisms underlying NPS, such as aggression, anxiety, and sleep disturbances, with the goal of identifying potential therapeutic targets for interventions. The funding opportunity is open to a diverse range of applicants, including universities, non-profits, and governmental agencies, with applications accepted until September 7, 2026. Interested parties can find more information and submit inquiries via email at grantsinfo@nih.gov, and further details are available at the NIH grants website.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting research grant applications for the "Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline" initiative. This funding opportunity aims to collect pilot data to support early-stage testing of both pharmacological and non-pharmacological interventions targeting cognitive and neuropsychiatric changes associated with Alzheimer's Disease (AD) and related dementias (ADRD). The initiative is crucial in addressing the public health crisis posed by these conditions, emphasizing the need for effective therapies and improved trial designs. Interested applicants can apply for grants with an award ceiling of $325,000, with applications due by November 18, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" grant, aimed at advancing research on Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity seeks to support high-priority research initiatives that address the growing public health crisis posed by these conditions, particularly among older adults. Eligible applicants include a diverse range of entities such as educational institutions, non-profits, and tribal governments, with funding decisions based on the scientific merit of proposals and the qualifications of the investigators. Applications are due by November 12, 2024, and interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)" through a U01 cooperative agreement mechanism. This initiative aims to support the optimization of promising genome editing-based therapeutic leads for ADRD, focusing on preparing these candidates for Investigational New Drug (IND)-enabling studies. The funding is crucial for advancing research in various forms of ADRD, including Frontotemporal Dementia and Lewy Body Dementia, by refining therapeutic candidates to ensure their safety and efficacy. Interested applicants can apply for up to $1 million in funding, with a total budget commitment of up to $3 million per year for two awards, and must submit their applications by November 19, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for early and late-stage clinical trials focused on Alzheimer's Disease (AD) and related dementias, as well as age-related cognitive decline. This initiative aims to develop and implement both pharmacological and non-pharmacological interventions to address cognitive and neuropsychiatric changes associated with these conditions, while also encouraging innovative trial designs and methodologies. Given the significant public health crisis posed by AD, which currently affects over six million Americans, this funding opportunity is part of a broader strategy to enhance research and develop effective therapies across the disease spectrum. Applications are due by January 7, 2025, and interested parties can find more information and submit proposals through the NIH ASSIST online system or contact NIH Grants Information at grantsinfo@nih.gov.